Industry Newsveterinary diagnosticsdiagnostics instrumentsidxx
IDEXX Laboratories Reports Strong 2025 Results
7.2
Published Feb. 7, 2026, IDEXX Laboratories reported robust 2025 results, including fourth-quarter revenue of $1.09 billion and full-year revenue of $4.30 billion; 2025 EPS was $13.08, up 14% year-over-year. The company recorded over 1,900 inVue Dx instrument placements, generated $1.1 billion free cash flow, and issued 2026 guidance of $4.63–$4.72 billion revenue and $14.29–$14.80 EPS.
Key Points
- 1Reports strong 2025 results: $4.30B revenue, $13.08 EPS, 14% EPS growth year-over-year.
- 2Highlights operational strength with expanded margins, $1.1B free cash flow, and record inVue Dx placements.
- 3Signals durable companion-animal demand and instrument-driven recurring revenue supporting 2026 guidance and shareholder returns.
Scoring Rationale
Solid, official 2025 results and 2026 guidance drive relevance; limited novelty and promotional framing reduce transformative impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
